Project Details
Description
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifoca
| Status | Active |
|---|---|
| Effective start/end date | 10/1/21 → 9/30/25 |
Funding
- PPD INVESTIGATOR SERVICES, LLC
- ARGENX
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.